Cefodox sus 100 mg/5ml

Pajjiż: Ġordan

Lingwa: Ingliż

Sors: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Ingredjent attiv:

Cefpodoxime (Proxetil) 100 mg/5ml

Disponibbli minn:

الشركة الدولية للدواء - Pharma International Company

Kodiċi ATC:

J01DD13

INN (Isem Internazzjonali):

Cefpodoxime (Proxetil) 100 mg/5ml

Dożaġġ:

100 mg/5ml

Unitajiet fil-pakkett:

50 ml

Manifatturat minn:

Pharma International Company/Jordan (الاردن)

Sommarju tal-prodott:

8.91 :سعر الجمهور + الضريبة

Fuljett ta 'informazzjoni

Approved by: Amani AlAloul, Abdalrahim Mahmoud Ismail, Abed Al-hamdan,
Eman Jaber on 14/10/2017
_REV.DATE APR 2016 I 021 04_
COMPOSITION
CEFODOX
® 100MG TABLET:
Each tablet contains Cefpodoxime proxetil equivalent to 100 mg
Cefpodoxime.
CEFODOX
® 200MG TABLET:
Each tablet contains Cefpodoxime proxetil equivalent to 200 mg
Cefpodoxime.
CEFODOX
® 50MG DRY SUSPENSION:
Each 5 ml contains Cefpodoxime proxetil equivalent to 50 mg
Cefpodoxime.
CEFODOX
®
100MG DRY SUSPENSION:
Each 5 ml contains Cefpodoxime proxetil equivalent to 100 mg
Cefpodoxime.
CEFODOX
®
40MG DRY SUSPENSION:
Each 5 ml contains Cefpodoxime proxetil equivalent to 40 mg
Cefpodoxime.
_PHARMACOLOGICAL PROPERTIES_
CEFODOX
®
(Cefpodoxime proxetil) is an orally active, broad spectrum;
semisynthetic third generation
cephalosporin.
Cefpodoxime proxetil is a prodrug that undergoes de-esterification to
the active metabolite Cefpodoxime.
Cefpodoxime proxetil is
rapidly absorbed after oral administration reaching peak plasma
conentration
within 2-3 hours.
It is widely distributed to most body tissues reaching a concentration
higher than MIC
90
of S. pyogenes in tonsil tissues for more than 7 hours & a higher
conentration than MIC
90
of Streptococcus
pneumoniae & H. influenzae in lung tissues for more than 12 hours.
Cefpodoxime proxetil undergoes
minimal metabolism & almost 33% of the dose is excreted unchanged
renally.
Cefpodoxime proxetil inhibits bacterial cell wall synthesis & exerts a
bactericidal activity against a wide
range of gram positive & gram negative bacteria with a high stability
in the presence of beta lactamase
enzymes. It is usually active against the following organisms in vitro
& in clinical infections:
G +VE AEROBES
- Streptococcus pneumoniae.
- Streptococcus pyogenes.
- Staphylococcus aureus (including β lactamase producing strains).
- Staphylococcus saprophyticus.
G -VE AEROBES
- Escherichia coli.
- Haemophilus influenzae (including β lactamase producing strains).
- Klebsiella pneumoniae.
- Moraxella (Branhamella)catarrhalis ( includi